Primary Pain Palliation in Bone Metastases Treated With Magnetic Resonance-guided Focused Ultrasound
Recruitment status was: Enrolling by invitation
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Magnetic Resonance guided Focused Ultrasound (MRgFUS) has demonstrated to be effective for pain control through thermally-induced cell death and periosteal denervation caused by cortical heating relative to acoustic energy absorption. There is also evidence that a high intensity focused ultrasound beam can penetrate through the cortical bone to the medullary space, producing thermal necrosis of cancer tissue. However, little is known about the potential effects of MRgFUS as first line therapeutic modality for pain palliation in skeletal metastases.
Our hypothesis sought to assess the clinical performance of MRgFUS primary treatment of painful bone metastases and determine the potential of this technique for local tumor control.
| Condition | Intervention | Phase |
|---|---|---|
| Secondary Malignant Neoplasm of Bone | Procedure: MRgFUS | Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
| Official Title: | Primary Pain Palliation and Local Tumor Control in Bone Metastases Treated With Magnetic Resonance-guided Focused Ultrasound |
- To evaluate the safety and efficacy of Magnetic Resonance-guided Focused Ultrasound (MRgFUS) for the primary treatment of painful bone metastases [ Time Frame: 6 months ]Patients will be monitored for major or minor adverse events
- To correlate the treatment response to extent of tumor necrosis as determined by follow-up imaging [ Time Frame: 6 months ]necrosis of the actual lesion will be analyzed according to area on non-perfused volume at the end of the procedure
| Enrollment: | 18 |
| Study Start Date: | January 2011 |
| Estimated Study Completion Date: | February 2015 |
| Estimated Primary Completion Date: | January 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
MRgFUS
High intensity focused ultrasound energy, delivered under the guidance of the MR images (MgFUS) allows for a predefined amount of energy to be delivered in the desired target (Metastasis). Bone readily absorbs focused ultrasound energy resulting in a thermo-related neurolysis of the periostium with consequent pain palliation. The amount of energy delivered can be modulated with the objective to penetrate cortical space and obtain necrosis of the metastasis thus preventing local recurrence.
|
Procedure: MRgFUS
Focused ultrasound energy is accumulated into the target tissue (skeletal metastasis) thanks to the real time guidance of the MR images.
Other Names:
|
Detailed Description:
Unlike previous studies, in which patients were enrolled for MRgFUS treatment because of the failure of other therapies, our study will be conducted in patients not previously treated with EBRT to the targeted lesion.
This is an important new feature, especially given the advantages of MRgFUS, such as lack of ionizing radiation, the ability to conduct treatment on an outpatient basis and the possibility to repeat the treatment as necessary.
Eligibility
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 90 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- the presence of a known primary cancer and bone metastases confirmed by two or more imaging modalities;
- exhaustion or refusal of all other pain palliation methods including EBRT;
- confirmation of MRgFUS treatment feasibility at a preliminary MR planning examination (presence of an adequate acoustic window between the transducer, skin and target lesion and absence of bowel loops across the planned ultrasound path)
Exclusion Criteria:
- general contraindication to MR imaging (including pacemaker, ferromagnetic devices or implants)
- general contraindication to gadolinium-based contrast agents (intolerance and/or clinically proven chronic renal failure)
- general contraindication to general/epidural anesthesia or deep sedation
Contacts and Locations
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01693770
| Italy | |
| Policlinico Umberto I | |
| Rome, Italy, 00100 | |
| Principal Investigator: | Alessandro Napoli, MD, PhD | Department of Radiological Sciences, Sapienza University of Rome |
More Information
| Responsible Party: | Alessandro Napoli, MD, PhD, University of Roma La Sapienza |
| ClinicalTrials.gov Identifier: | NCT01693770 History of Changes |
| Other Study ID Numbers: |
BM-MRgFUS |
| First Submitted: | September 20, 2012 |
| First Posted: | September 26, 2012 |
| Last Update Posted: | June 18, 2014 |
| Last Verified: | June 2014 |
Keywords provided by Alessandro Napoli, University of Roma La Sapienza:
|
Bone Metastasis Pain Palliation High Intensity Focused Ultrasound |
Additional relevant MeSH terms:
|
Neoplasm Metastasis Neoplasms Neoplasms, Second Primary Bone Neoplasms Bone Marrow Diseases Neoplastic Processes |
Pathologic Processes Neoplasms by Site Bone Diseases Musculoskeletal Diseases Hematologic Diseases |